The 26-day notice: how a compounding wind-down works in Denmark
The document is four pages. Three of them are about dates.
The archive
Page 94 of 170 of this archive, newest first.
The relabeller trading as Vantris Bio closes after 24 years
A proper account of an operation that existed, and of what closing it cost.
Poland health authority warns on falsified semaglutide pens
Reported from the analysis, not from a warning notice.
WWB declines, for the 14th time, to name its synthesis house
Documentation practice is the only part of vendor quality a buyer can assess before purchase.
The trade has decided the ceiling is arbitrary. The trials disagree.
Higher doses of these molecules have been studied. In general they produced modest additional efficacy and disproportionate additional symptom burden, which is why the…
Why a dead-clean sterile filter can pass pyrogen straight through
The limit for a parenteral product is calculable from the dose and the body weight in two lines. Almost nobody in this trade performs the calculation.
What a 15% rise in coupling-reagent prices does to a 30 mg vial
Follow the resin, not the catalogue.
Janoshik result on a Hong Kong cagrilintide lot lands 3.6 points below the supplier’s figure
The report states the gradient, the wavelength and the integration threshold, which is more than most.
Holograms, QR codes and other things that are not verification
Reported from the analysis, not from a warning notice.
SURMOUNT-3 extension data: what happens after the trial stops
A design note rather than a result: what the comparator was, and what that permits you to conclude.
How a claim degrades between the bench and the listing
A badge asserts that something was tested. It does not assert what, when, on whose sample, by what method, or whether the lot on sale is the lot that was tested.
What the GLP-1 receptor actually does when tirzepatide binds it
The class is described as though every molecule in it did the same thing. At the receptor, they demonstrably do not.
What the new the United Kingdom guidance says about stopping
The evidence base is thin and the document says so, which is to its credit.
Nantong export categories for peptide intermediates were quietly renamed
Follow the resin, not the catalogue.
Independent analysis puts a SGN liraglutide lot at 97.4%, against 93.3% on the certificate
A reminder that a purity figure is the output of a method, and that methods differ.
The quiet end of Calder Vale Peptides of Skipton
A proper account of an operation that existed, and of what closing it cost.
A shortage listing ends. 24 pharmacies now have a business model and no legal basis for it.
The document is four pages. Three of them are about dates.
Side effects, cost, supply, target: four reasons with four trajectories
Why the reason for stopping changes what happens afterwards.
A few hundred participants carry the whole body-composition argument
A substudy powered to describe a mean is not a substudy powered to detect a clinically meaningful individual change.
Inspectors cite the relabeller trading as Vantris Bio over sterility assurance
The observation that closes a facility is rarely the dramatic one.
What a 13% rise in coupling-reagent prices does to a 10 mg vial
Follow the resin, not the catalogue.
PeptideMeter result on a Zhuhai mazdutide lot lands 2.7 points below the supplier’s figure
The result is unremarkable. What the report omits is not.
Calder Vale Peptides of Skipton closes after 6 years
A proper account of an operation that existed, and of what closing it cost.
The reference change value: the number that tells you whether a delta is real
A flag is a probability statement about a population. It is not a statement about the person holding the printout.
Two documents, two disciplines: purity and sterility are not the same trade
Every certificate circulating in this market answers a question about molecules. Almost none answers a question about organisms, pyrogens, or the integrity of the seal.
Maximum tolerated is not maximum approved
A plateau at an intermediate dose and a plateau at the maximum dose look identical from the outside and mean different things.
The slide that was not in the abstract
Reported from the sessions, and from the two hours afterwards.
Independent analysis puts a CPC dulaglutide lot at 95.9%, against 94.7% on the certificate
The supplier has not disputed the finding. It has not explained the gap either.
TRIUMPH-3 misses on a secondary endpoint the coverage has not mentioned
A design note rather than a result: what the comparator was, and what that permits you to conclude.
What the new Germany guidance says about stopping
The evidence base is thin and the document says so, which is to its credit.